深圳信立泰药业股份有限公司 2015 年半年度报告全文 深圳信立泰药业股份有限公司 2015 年半年度报告 2015 年 08 月 1 深圳信立泰药业股份有限公司 2015 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 没有董事、监事、高级管理人员声明对半年度报告内容的真实性、准确性、 完整性无法保证或存在异议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人叶澄海、主管会计工作负责人刘军及会计机构负责人（会计主 管人员）徐冬美声明：保证本半年度报告中财务报告的真实、准确、完整。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 2 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 李中军 独立董事 公务 韩文君 蔡俊峰 董事 公务 杨健锋 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 2 | ...

深圳信立泰药业股份有限公司 2015 年第一季度报告正文 证券代码：002294 证券简称：信立泰 公告编号：2015-017 深圳信立泰药业股份有限公司 2015 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人叶澄海、主管会计工作负责人刘军及会计机构负责人（会计主 管人员）徐冬美声明：保证季度报告中财务报表的真实、准确、完整。 1 深圳信立泰药业股份有限公司 2015 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 783,030,516.96 | 650,917,020.39 | 20.30% | | 归属于上市公司股东的净利润（元） | 313,574 ...

深圳信立泰药业股份有限公司 2014 年年度报告全文 深圳信立泰药业股份有限公司 2014 年年度报告 2015 年 03 月 1 深圳信立泰药业股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 没有董事、监事、高级管理人员声明对年度报告内容的真实性、准确性、 完整性无法保证或存在异议。 公司经本次董事会审议通过的利润分配预案为：以 2014 年 12 月 31 日的公 司总股本 653,760,000 股为基数，向全体股东每 10 股派发现金红利 7.00 元（含 税），送红股 0 股（含税），以资本公积金向全体股东每 10 股转增 6 股。 公司负责人叶澄海、主管会计工作负责人刘军及会计机构负责人（会计主 管人员）徐冬美声明：保证年度报告中财务报告的真实、准确、完整。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 2 | 目录 | | --- | ...

Financial Performance - Operating revenue for the reporting period was ¥679,287,177.42, representing a year-on-year growth of 20.70%[4] - Net profit attributable to shareholders of the listed company was ¥256,140,870.24, up 28.19% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥254,152,264.42, an increase of 27.21% year-on-year[4] - Basic earnings per share for the reporting period were ¥0.39, reflecting a growth of 25.81%[4] - The estimated net profit attributable to shareholders for 2014 is expected to range from 99,649.99 million to 107,954.16 million RMB, representing a growth of 20.00% to 30.00% compared to the previous year[21] - The net profit for 2013 attributable to shareholders was 83,041.66 million RMB, indicating a stable growth in sales of the company's formulation products[21] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,904,559,939.47, an increase of 7.17% compared to the end of the previous year[4] - Net assets attributable to shareholders of the listed company amounted to ¥3,488,432,591.11, reflecting an increase of 11.48% year-on-year[4] - Other current assets increased by CNY 300.20 million, a growth of 149.69%, mainly due to the purchase of financial products during the reporting period[14] - Deferred tax assets increased by CNY 12.51 million, a growth of 31.72%, primarily due to the increase in unrealized internal transactions during the reporting period[14] - Accounts payable decreased by CNY 64.29 million, a reduction of 38.48%, mainly due to the decrease in payable engineering and equipment costs during the reporting period[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥678,387,934.43, an increase of 44.23%[4] - Cash received from sales of goods and services increased by CNY 520.25 million, a growth of 34.62%, mainly due to increased sales and cash receipts[14] - Cash paid for other operating activities increased by CNY 160.30 million, a growth of 46.55%, primarily due to increased expenses during the reporting period[14] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets decreased by CNY 218.22 million, a reduction of 56.88%, mainly due to prepayments made in the previous period for the acquisition of production technology[15] - Cash paid for investments increased by CNY 502.00 million, a growth of 502.00%, primarily due to the purchase of financial products during the reporting period[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,409[9] - The largest shareholder, Xintai Pharmaceutical Co., Ltd., holds 71.56% of the shares, totaling 467,812,800 shares[9] Compliance and Investments - The company has not engaged in any securities investments during the reporting period[22] - The company does not hold shares in any other listed companies during the reporting period[23] - The commitments made by the company's controlling shareholders have been fulfilled without any violations[20] Non-Recurring Items - Non-recurring gains and losses for the year-to-date totaled ¥7,030,349.09[6]

Financial Performance - The company's operating revenue for the first half of 2014 was CNY 1,303,758,655.12, representing a 22.81% increase compared to CNY 1,061,568,217.04 in the same period last year[19]. - The net profit attributable to shareholders was CNY 495,255,724.16, reflecting a growth of 26.07% from CNY 392,836,855.59 year-on-year[19]. - Basic and diluted earnings per share rose to CNY 0.76, up 26.67% from CNY 0.60 in the same period last year[19]. - The net cash flow from operating activities increased by 112.87%, reaching CNY 452,810,938.19, compared to CNY 212,719,519.32 in the previous year[19]. - The company achieved a main business revenue of CNY 1,303,758,655.12, representing a year-on-year growth of 22.81%[29]. - The net profit for the first nine months of 2014 is expected to be between RMB 711.17 million and RMB 770.44 million, representing a year-on-year increase of 20.00% to 30.00%[64]. - The net profit for the first nine months of 2013 was RMB 592.65 million, indicating a stable growth in the sales of the company's formulation products[64]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,946,377,935.55, an increase of 8.32% from CNY 3,643,252,581.73 at the end of the previous year[19]. - The total assets of Shenzhen Xinlitai Pharmaceutical Co., Ltd. increased to CNY 3,946,377,935.55 from CNY 3,643,252,581.73, reflecting a growth of approximately 8.35%[123]. - The company's total current assets rose to CNY 2,516,290,915.34, up from CNY 2,261,937,765.94, indicating an increase of about 11.25%[121]. - Total liabilities increased to CNY 705,070,686.62 from CNY 508,363,370.80, reflecting a rise of about 38.73%[122]. - The company's total equity increased to CNY 3,241,307,248.93 from CNY 3,134,889,210.93, indicating a growth of approximately 3.39%[122]. Investment and R&D - The company plans to accelerate the promotion of new products and explore the development of biomedicine and medical services[26]. - Research and development investment decreased by 7.52% to CNY 60,635,606.80[30]. - The company has invested CNY 6,000 million in new drug research and development, which has been completed[52]. - The company has allocated CNY 4,500 million for the acquisition of industrial land in Huizhou, which has been completed[52]. - The R&D project for Cefuroxime Sodium and Sulbactam is currently in the third phase of clinical implementation[54]. Fundraising and Financial Management - Total fundraising amount reached RMB 114,278.97 million, with RMB 2,379.83 million invested during the reporting period[46]. - The total amount of fundraising repurposed is RMB 6,800 million, accounting for 5.95% of the total fundraising[46]. - The company has established a three-party supervision agreement for the management of fundraising funds, ensuring compliance with regulations[49]. - The company plans to invest idle funds in financial products, aiming to optimize asset management[99]. Corporate Governance and Compliance - The company maintained compliance with corporate governance regulations and did not receive any administrative regulatory measures from supervisory authorities[71]. - There were no major litigation or arbitration matters during the reporting period[72]. - The company has not engaged in derivative investments or entrusted loans during the reporting period[43][44]. - The company has committed to avoiding any business that competes directly or indirectly with its operations, ensuring compliance with this commitment[97]. Shareholder Information - The total number of shares is 653,760,000, with 56.10% being restricted shares and 43.90% being unrestricted shares[102]. - The company implemented a cash dividend policy, distributing RMB 6 per 10 shares to all shareholders based on the total share capital of 653,760,000 shares as of December 31, 2013[64]. - The cash dividend distribution was executed on May 7, 2014, with specific tax treatments for different categories of shareholders[65]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[67]. Market Position and Strategy - The company successfully obtained production licenses for new products, enhancing its competitive advantage and profitability[32]. - The sales strategy was adjusted to maintain market leadership, with a focus on academic promotion and tendering for new products[34]. - The company’s core competitiveness remains strong, supported by a robust product structure and professional R&D team[37]. Financial Reporting and Audit - The financial report was approved by the board of directors on August 15, 2014[167]. - The company did not conduct an audit for the semi-annual financial report[118]. - The company has not completed its financial audit for the semi-annual report, which may impact investor confidence[98].

Financial Performance - The company's operating revenue for Q1 2014 was ¥650,917,020.39, representing a 23.3% increase compared to ¥527,905,285.73 in the same period last year[5] - Net profit attributable to shareholders was ¥254,161,295.12, up 25.87% from ¥201,922,542.26 year-on-year[5] - Basic earnings per share rose to ¥0.39, reflecting a 25.81% increase from ¥0.31 in the same period last year[7] - The net profit attributable to shareholders for the first half of 2014 is expected to increase by 20% to 30%, ranging from CNY 471.40 million to CNY 510.69 million[22] - The net profit for the first half of 2013 was CNY 392.84 million, indicating a significant growth in profitability[22] - The stable growth in the sales of the company's formulation products is contributing to the increased profit margin[22] Cash Flow - The net cash flow from operating activities increased by 88.81% to ¥197,570,853.09, compared to ¥104,642,080.08 in the previous year[7] - Net cash flow from operating activities increased by 88.81% in Q1 2014 compared to the same period last year, with cash received from sales of goods and services rising by 30.88%[15] - Net cash flow from investing activities increased by 53.13% in Q1 2014 compared to the same period last year, primarily due to reduced payments for equipment and project costs[15] Assets and Shareholder Information - Total assets at the end of the reporting period were ¥3,855,198,310.82, a 5.82% increase from ¥3,643,252,581.73 at the end of the previous year[7] - The net assets attributable to shareholders increased by 8.12% to ¥3,383,484,371.84 from ¥3,129,334,353.76 at the end of the previous year[7] - The total number of shareholders at the end of the reporting period was 32,682[9] - The largest shareholder, Xinlitai Pharmaceutical Co., Ltd., holds 71.56% of the shares, amounting to 467,812,800 shares[9] - The company did not engage in any repurchase transactions during the reporting period[12] Receivables and Expenses - As of March 2014, accounts receivable interest increased by 112.14% compared to the end of 2013, primarily due to interest income from financial products accrued during the period[15] - Other receivables grew by 36.79% as of March 2014 compared to the end of 2013, attributed to the expansion of the company's operations and an increase in sales and management personnel[15] - As of March 2014, employee compensation payable decreased by 57.34% compared to the end of 2013, mainly due to the distribution of year-end bonuses accrued in 2013[15] - Management expenses increased by 32.19% in Q1 2014 compared to the same period last year, driven by the expansion of the company's scale and increased R&D investment[15] Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥1,747,577.69 for the period[8]

Financial Performance - The company's operating revenue for 2013 was CNY 2,327,483,505.65, representing a 27.26% increase compared to CNY 1,828,881,533.32 in 2012[24] - The net profit attributable to shareholders for 2013 was CNY 830,416,581.75, a growth of 30.74% from CNY 635,167,523.74 in 2012[24] - The basic earnings per share for 2013 was CNY 1.27, up 30.93% from CNY 0.97 in 2012[24] - The total assets at the end of 2013 reached CNY 3,643,252,581.73, marking a 22.23% increase from CNY 2,980,719,190.10 at the end of 2012[24] - The net assets attributable to shareholders at the end of 2013 were CNY 3,129,334,353.76, a 20.17% increase from CNY 2,603,984,161.36 in 2012[24] - The net cash flow from operating activities for 2013 was CNY 668,521,964.86, reflecting a 28.26% increase from CNY 521,213,683.56 in 2012[24] - The weighted average return on equity for 2013 was 29.49%, an increase of 2.36% from 27.13% in 2012[24] Dividend Distribution - The company plans to distribute a cash dividend of CNY 6.00 per 10 shares to shareholders based on the total share capital as of December 31, 2013[4] - The proposed cash dividend for 2013 is 6.00 RMB per 10 shares, totaling 392,256,000 RMB[145] - The cash dividend distribution for 2013 represents 47.24% of the net profit attributable to shareholders[147] - The company has maintained a cash dividend policy where the total cash dividends over the past three years exceeded 30% of the average distributable profit[139] - The cash dividend for 2012 was 7.00 RMB per 10 shares, amounting to 305,088,000 RMB, which was 48.03% of the net profit[147] - The cash dividend for 2011 was 4.50 RMB per 10 shares, totaling 163,440,000 RMB, representing 40.33% of the net profit[147] - The company has not made any adjustments to its cash dividend policy during the reporting period[140] - The company plans to allocate 10% of the net profit to statutory reserves as per legal requirements[145] - The actual profit available for distribution to investors in 2013 was CNY 1,643,939,873.39, after adding undistributed profits from previous years[148] Research and Development - R&D investment reached CNY 144.21 million, a year-on-year increase of 13.62%, reflecting the company's commitment to innovation[34] - The company obtained 17 patents in 2013, including several for new drug formulations and medical devices, enhancing its intellectual property portfolio[51] - The company received clinical trial approval for its drug Cipro in 2013, indicating progress in its product development pipeline[55] - The company is focused on expanding its market presence through new product development and strategic patent acquisitions[51] - The company's R&D expenditure was $14.42 million, accounting for 6.20% of total revenue, aimed at enhancing innovative drug development[71] - The proportion of R&D expenditure excluding prepaid and development expenses remained stable at 6.20% of operating income in 2013[49] - The company aims to accelerate the R&D process of new products and improve the quality of existing products, with a focus on optimizing production quality management systems[125] Market and Sales Performance - The company achieved a main business revenue of CNY 2,326.98 million in 2013, representing a year-on-year growth of 27.90%[36] - The sales of formulation products increased by 34.97% compared to the previous year, indicating a strengthening marketing network and promotional efforts[36] - The total sales volume for 2013 was 111,757,493.3 units, a 15.65% increase from 2012, while production volume rose by 9.46%[39] - Sales expenses increased by 31.18% to 594.47 million yuan in 2013, primarily due to the expansion of the sales scale of formulation products[48] - The company’s operating income growth was supported by increased marketing costs due to expanded sales efforts[48] Financial Management - The company reported a decrease in non-operating income from CNY 24,715,289.89 in 2012 to CNY 20,805,770.29 in 2013[26] - The company reported a 24.79% increase in income tax expenses, totaling 143.17 million yuan in 2013[48] - The financial expenses decreased by 25.25% to -16.45 million yuan, indicating improved financial management[48] - The company has ongoing applications for several patents, including a method for preparing Clopidogrel and its intermediates, which was filed in May 2013[54] Production and Operations - The company’s production base in Daya Bay received EU certification and passed domestic GMP certification, enhancing its production capabilities[35] - The inventory level decreased by 32.98% year-on-year, attributed to production facility upgrades and increased stock in the previous year[39] - The company completed the investment project for the raw material drug and its formulation of Clopidogrel Hydrogen Sulfate with a total investment of 16,520 million, achieving 100% completion[93] - The project for the high-tech industrialization of Cefoperazone Sodium and Cefotaxime Sodium was completed with an investment of 9,606.53 million, reaching 99.45% of the planned investment[93] - The company is currently developing new products and technologies, including the research project for Cefuroxime Sodium, which has reached 89.88% completion[93] Risk Management - The company has identified risks related to national policy changes and cost increases, which are detailed in the board report section[13] - The company faces risks related to changes in national policies and bidding policies that may impact market competition and sales[132] Corporate Governance and Compliance - The company has maintained compliance with all regulatory requirements regarding guarantees and commitments[185] - There were no significant legal disputes or media controversies reported during the period[161][162] - The company has fulfilled all commitments made to minority shareholders in a timely manner[190] - The company has not reported any violations of commitments, indicating strong governance practices[188] Subsidiaries and Investments - The company established a new wholly-owned subsidiary, Dezhou Zhizhi Pharmaceutical Chemical Technology Co., Ltd., during the reporting period[137] - The company completed a capital increase for Shenzhen Sinopharm Biomedical Engineering Co., which is currently in the clinical trial phase[96] - Shenzhen Xinlitai Biomedical Engineering Co., Ltd. is focused on the production and R&D of Class II and III medical devices, with a valid production license until June 29, 2014[108] Auditor and Financial Reporting - The company appointed Ruihua Certified Public Accountants (Special General Partnership) as the auditor for the 2013 fiscal year, with an audit fee of RMB 460,000[192] - The company has not disclosed any non-standard audit reports for the reporting period[196] - The company has engaged Ruihua Certified Public Accountants for internal control auditing, with total fees amounting to RMB 460,000[195]